[
  {
    "text": "2.5",
    "bbox": [
      108,
      79,
      138,
      93
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Each Party may change its Agreement Administrators, at any time, with written notice to the other Party.",
    "bbox": [
      179,
      80,
      958,
      93
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "3.0",
    "bbox": [
      109,
      96,
      138,
      108
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Costs and Expenses",
    "bbox": [
      179,
      97,
      332,
      108
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "3.1",
    "bbox": [
      109,
      112,
      138,
      125
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Upon execution of this Agreement and acceptance of iBio's proposal for the development of a Plant-Made Rituximab, and in consideration",
    "bbox": [
      180,
      113,
      1000,
      125
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "for providing the technology transfer contemplated herein, CC-Pharming shall pay iBio [***], which shall be paid as follows:",
    "bbox": [
      179,
      128,
      1000,
      141
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "3.1.1",
    "bbox": [
      179,
      144,
      214,
      156
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "First payment of [***] is required to initiate the project: [***].",
    "bbox": [
      247,
      145,
      713,
      157
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "3.1.2",
    "bbox": [
      178,
      161,
      215,
      172
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Second payment of [***]. Due upon presentation of the following deliverables:",
    "bbox": [
      247,
      161,
      842,
      173
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "a)",
    "bbox": [
      247,
      178,
      265,
      189
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Detailed design drawings of the pilot plant;.",
    "bbox": [
      278,
      176,
      606,
      189
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "b)",
    "bbox": [
      245,
      192,
      266,
      205
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Schematic design of the commercial facility;.",
    "bbox": [
      279,
      192,
      608,
      205
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "c)",
    "bbox": [
      247,
      209,
      262,
      221
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Purified antibody for pre-clinical testing and development; and",
    "bbox": [
      279,
      209,
      753,
      221
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "d)",
    "bbox": [
      247,
      224,
      265,
      237
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "The quality management system (QMS) development up to and including governance documents and governance standard",
    "bbox": [
      279,
      225,
      1000,
      237
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "operating procedures (SOP's).",
    "bbox": [
      281,
      240,
      508,
      254
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "3.1.3",
    "bbox": [
      178,
      256,
      215,
      268
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Final payment of [***], due upon presentation of the following deliverables:",
    "bbox": [
      247,
      257,
      820,
      269
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "a)",
    "bbox": [
      247,
      275,
      262,
      284
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Detailed Design drawings for the commercial facility;",
    "bbox": [
      279,
      273,
      676,
      284
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "b)",
    "bbox": [
      246,
      288,
      265,
      300
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Completion of QMS documentation for rituximab including batch records, release documents, and assay SOPs;",
    "bbox": [
      279,
      288,
      1000,
      301
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "c)",
    "bbox": [
      246,
      305,
      262,
      318
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Completion of all training sessions and training documentation;",
    "bbox": [
      280,
      305,
      760,
      317
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "d)",
    "bbox": [
      247,
      320,
      263,
      333
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Delivery of antibody drug substance for clinical trials; and",
    "bbox": [
      279,
      320,
      721,
      333
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "e)",
    "bbox": [
      247,
      337,
      262,
      349
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Completion of a chemistry, manufacturing, and controls (CMC) document to support an (investigational new drug",
    "bbox": [
      280,
      336,
      1000,
      349
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "application (IND) or equivalent.",
    "bbox": [
      282,
      352,
      519,
      366
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "4.0",
    "bbox": [
      110,
      368,
      138,
      381
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Inventions",
    "bbox": [
      179,
      369,
      259,
      380
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "4.1",
    "bbox": [
      110,
      384,
      138,
      396
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Inventorship of inventions, developments, or discoveries first conceived or actually reduced to practice under this Agreement.",
    "bbox": [
      179,
      384,
      1000,
      397
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "(\"Agreement Inventions\") will be determined under U.S. Patent Law. All inventions, developments, or discoveries made solely by iBio.",
    "bbox": [
      179,
      400,
      1000,
      413
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "prior to this Agreement is, and shall be, the sole property of iBio. All inventions, developments, or discoveries made solely by CC-",
    "bbox": [
      179,
      416,
      1000,
      429
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Pharming thereof prior to this Agreement is, and shall be, the sole property of CC-Pharming",
    "bbox": [
      179,
      432,
      866,
      445
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "4.2",
    "bbox": [
      110,
      448,
      138,
      461
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "All rights to inventions, patentable or non-patentable, made solely by employees of iBio during the term of this Agreement shall belong",
    "bbox": [
      179,
      448,
      1000,
      461
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "solely to iBio. All rights to inventions, patentable or non-patentable, made solely by employees of CC-Pharming during the term of this",
    "bbox": [
      180,
      465,
      1000,
      477
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Agreement shall belong solely to CC-Pharming. All rights to Agreement Inventions, patentable or non-patentable, made jointly by",
    "bbox": [
      180,
      481,
      1000,
      493
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "employees of iBio and employees of CC-Pharming (\"Joint Inventions\") will belong jointly to iBio and CC-Pharming, with inventorship.",
    "bbox": [
      179,
      496,
      1000,
      509
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "determined as described in 35 U.S.C. s 262 and (Chin Patent Law). The Parties contemplate that each will benefit from Joint Inventions, as",
    "bbox": [
      179,
      512,
      1000,
      525
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "such, iBio will be responsible for direct control over the drafting and prosecution of any patents to Joint Inventions, with copy to CC-.",
    "bbox": [
      180,
      529,
      1000,
      541
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Pharming. The parties shall share equally in the costs of patent protection for Joint Inventions.",
    "bbox": [
      179,
      544,
      891,
      557
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Master Joint Development Agreement iBio CC-Pharming.",
    "bbox": [
      111,
      574,
      538,
      590
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Page 4 of 12",
    "bbox": [
      1000,
      575,
      1000,
      590
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Source: IBIO, INC., 8-K, 3/13/2020",
    "bbox": [
      134,
      1000,
      412,
      1000
    ],
    "label": 18,
    "category": "Anti-Assignment"
  }
]